Molecular	O
serum	B:C0229671
signature	O
of	O
treatment	O
resistant	I:C2063866
depression	I:C2063866
.	O

Molecular	O
serum	O
signature	B:C0005516
of	O
treatment	O
resistant	I:C2063866
depression	I:C2063866
.	O

Molecular	O
serum	O
signature	O
of	O
treatment	B:C2063866
resistant	I:C2063866
depression	I:C2063866
.	O

A	O
substantial	O
number	O
of	O
patients	O
suffering	O
from	O
major	B:C1269683
depressive	I:C1269683
disorder	I:C1269683
(	O
major	O
depressive	I:C1269683
disorder	I:C1269683
)	O
do	O
not	O
respond	O
to	O
multiple	O
trials	O
of	O
anti-depressants	O
,	O
develop	O
a	O
chronic	O
course	O
of	I:C0242656
disease	I:C0242656
and	O
become	O
treatment	O
resistant	O
.	O

A	O
substantial	O
number	O
of	O
patients	O
suffering	O
from	O
major	O
depressive	I:C1269683
disorder	I:C1269683
(	O
major	B:C1269683
depressive	I:C1269683
disorder	I:C1269683
)	O
do	O
not	O
respond	O
to	O
multiple	O
trials	O
of	O
anti-depressants	O
,	O
develop	O
a	O
chronic	O
course	O
of	I:C0242656
disease	I:C0242656
and	O
become	O
treatment	O
resistant	O
.	O

A	O
substantial	O
number	O
of	O
patients	O
suffering	O
from	O
major	O
depressive	I:C1269683
disorder	I:C1269683
(	O
major	O
depressive	I:C1269683
disorder	I:C1269683
)	O
do	O
not	O
respond	O
to	O
multiple	O
trials	B:C0008976
of	O
anti-depressants	O
,	O
develop	O
a	O
chronic	O
course	O
of	I:C0242656
disease	I:C0242656
and	O
become	O
treatment	O
resistant	O
.	O

A	O
substantial	O
number	O
of	O
patients	O
suffering	O
from	O
major	O
depressive	I:C1269683
disorder	I:C1269683
(	O
major	O
depressive	I:C1269683
disorder	I:C1269683
)	O
do	O
not	O
respond	O
to	O
multiple	O
trials	O
of	O
anti-depressants	B:C0003289
,	O
develop	O
a	O
chronic	O
course	O
of	I:C0242656
disease	I:C0242656
and	O
become	O
treatment	O
resistant	O
.	O

A	O
substantial	O
number	O
of	O
patients	O
suffering	O
from	O
major	O
depressive	I:C1269683
disorder	I:C1269683
(	O
major	O
depressive	I:C1269683
disorder	I:C1269683
)	O
do	O
not	O
respond	O
to	O
multiple	O
trials	O
of	O
anti-depressants	O
,	O
develop	O
a	O
chronic	O
course	B:C0242656
of	I:C0242656
disease	I:C0242656
and	O
become	O
treatment	O
resistant	O
.	O

A	O
substantial	O
number	O
of	O
patients	O
suffering	O
from	O
major	O
depressive	I:C1269683
disorder	I:C1269683
(	O
major	O
depressive	I:C1269683
disorder	I:C1269683
)	O
do	O
not	O
respond	O
to	O
multiple	O
trials	O
of	O
anti-depressants	O
,	O
develop	O
a	O
chronic	O
course	O
of	I:C0242656
disease	I:C0242656
and	O
become	O
treatment	B:C0087111
resistant	O
.	O

A	O
substantial	O
number	O
of	O
patients	O
suffering	O
from	O
major	O
depressive	I:C1269683
disorder	I:C1269683
(	O
major	O
depressive	I:C1269683
disorder	I:C1269683
)	O
do	O
not	O
respond	O
to	O
multiple	O
trials	O
of	O
anti-depressants	O
,	O
develop	O
a	O
chronic	O
course	O
of	I:C0242656
disease	I:C0242656
and	O
become	O
treatment	O
resistant	B:C1514892
.	O

Most	O
of	O
the	O
studies	O
investigating	O
molecular	O
changes	O
in	O
treatment	B:C2063866
-	I:C2063866
resistant	I:C2063866
depression	I:C2063866
(	O
treatment	O
-	I:C2063866
resistant	I:C2063866
depression	I:C2063866
)	O
have	O
only	O
examined	O
a	O
limited	O
number	O
of	O
molecules	O
and	O
genes	O
.	O

Most	O
of	O
the	O
studies	O
investigating	O
molecular	O
changes	O
in	O
treatment	O
-	I:C2063866
resistant	I:C2063866
depression	I:C2063866
(	O
treatment	B:C2063866
-	I:C2063866
resistant	I:C2063866
depression	I:C2063866
)	O
have	O
only	O
examined	O
a	O
limited	O
number	O
of	O
molecules	O
and	O
genes	O
.	O

Most	O
of	O
the	O
studies	O
investigating	O
molecular	O
changes	O
in	O
treatment	O
-	I:C2063866
resistant	I:C2063866
depression	I:C2063866
(	O
treatment	O
-	I:C2063866
resistant	I:C2063866
depression	I:C2063866
)	O
have	O
only	O
examined	O
a	O
limited	O
number	O
of	O
molecules	O
and	O
genes	B:C0017337
.	O

Consequently	O
,	O
biomarkers	B:C0005516
associated	O
with	O
treatment	O
-	I:C2063866
resistant	I:C2063866
depression	I:C2063866
are	O
still	O
lacking	O
.	O

Consequently	O
,	O
biomarkers	O
associated	O
with	O
treatment	B:C2063866
-	I:C2063866
resistant	I:C2063866
depression	I:C2063866
are	O
still	O
lacking	O
.	O

This	O
study	O
aimed	O
to	O
use	O
recently	O
advanced	O
high	B:C0872252
-	I:C0872252
throughput	I:C0872252
proteomic	I:C0872252
platforms	I:C0872252
to	O
identify	O
peripheral	O
biomarkers	O
of	O
treatment	O
-	I:C2063866
resistant	I:C2063866
depression	I:C2063866
defined	O
by	O
two	O
staging	O
models	I:C0449394
,	O
the	O
Thase	O
and	I:C0449394
Rush	I:C0449394
staging	I:C0449394
model	I:C0449394
(	O
Thase	O
and	I:C0449394
Rush	I:C0449394
staging	I:C0449394
model	I:C0449394
)	O
and	O
the	O
Maudsley	O
Staging	I:C0449394
Model	I:C0449394
(	O
Maudsley	O
Staging	I:C0449394
Model	I:C0449394
)	O
.	O

This	O
study	O
aimed	O
to	O
use	O
recently	O
advanced	O
high	O
-	I:C0872252
throughput	I:C0872252
proteomic	I:C0872252
platforms	I:C0872252
to	O
identify	O
peripheral	B:C0205100
biomarkers	O
of	O
treatment	O
-	I:C2063866
resistant	I:C2063866
depression	I:C2063866
defined	O
by	O
two	O
staging	O
models	I:C0449394
,	O
the	O
Thase	O
and	I:C0449394
Rush	I:C0449394
staging	I:C0449394
model	I:C0449394
(	O
Thase	O
and	I:C0449394
Rush	I:C0449394
staging	I:C0449394
model	I:C0449394
)	O
and	O
the	O
Maudsley	O
Staging	I:C0449394
Model	I:C0449394
(	O
Maudsley	O
Staging	I:C0449394
Model	I:C0449394
)	O
.	O

This	O
study	O
aimed	O
to	O
use	O
recently	O
advanced	O
high	O
-	I:C0872252
throughput	I:C0872252
proteomic	I:C0872252
platforms	I:C0872252
to	O
identify	O
peripheral	O
biomarkers	B:C0005516
of	O
treatment	O
-	I:C2063866
resistant	I:C2063866
depression	I:C2063866
defined	O
by	O
two	O
staging	O
models	I:C0449394
,	O
the	O
Thase	O
and	I:C0449394
Rush	I:C0449394
staging	I:C0449394
model	I:C0449394
(	O
Thase	O
and	I:C0449394
Rush	I:C0449394
staging	I:C0449394
model	I:C0449394
)	O
and	O
the	O
Maudsley	O
Staging	I:C0449394
Model	I:C0449394
(	O
Maudsley	O
Staging	I:C0449394
Model	I:C0449394
)	O
.	O

This	O
study	O
aimed	O
to	O
use	O
recently	O
advanced	O
high	O
-	I:C0872252
throughput	I:C0872252
proteomic	I:C0872252
platforms	I:C0872252
to	O
identify	O
peripheral	O
biomarkers	O
of	O
treatment	B:C2063866
-	I:C2063866
resistant	I:C2063866
depression	I:C2063866
defined	O
by	O
two	O
staging	O
models	I:C0449394
,	O
the	O
Thase	O
and	I:C0449394
Rush	I:C0449394
staging	I:C0449394
model	I:C0449394
(	O
Thase	O
and	I:C0449394
Rush	I:C0449394
staging	I:C0449394
model	I:C0449394
)	O
and	O
the	O
Maudsley	O
Staging	I:C0449394
Model	I:C0449394
(	O
Maudsley	O
Staging	I:C0449394
Model	I:C0449394
)	O
.	O

This	O
study	O
aimed	O
to	O
use	O
recently	O
advanced	O
high	O
-	I:C0872252
throughput	I:C0872252
proteomic	I:C0872252
platforms	I:C0872252
to	O
identify	O
peripheral	O
biomarkers	O
of	O
treatment	O
-	I:C2063866
resistant	I:C2063866
depression	I:C2063866
defined	O
by	O
two	O
staging	B:C0449394
models	I:C0449394
,	O
the	O
Thase	O
and	I:C0449394
Rush	I:C0449394
staging	I:C0449394
model	I:C0449394
(	O
Thase	O
and	I:C0449394
Rush	I:C0449394
staging	I:C0449394
model	I:C0449394
)	O
and	O
the	O
Maudsley	O
Staging	I:C0449394
Model	I:C0449394
(	O
Maudsley	O
Staging	I:C0449394
Model	I:C0449394
)	O
.	O

This	O
study	O
aimed	O
to	O
use	O
recently	O
advanced	O
high	O
-	I:C0872252
throughput	I:C0872252
proteomic	I:C0872252
platforms	I:C0872252
to	O
identify	O
peripheral	O
biomarkers	O
of	O
treatment	O
-	I:C2063866
resistant	I:C2063866
depression	I:C2063866
defined	O
by	O
two	O
staging	O
models	I:C0449394
,	O
the	O
Thase	B:C0449394
and	I:C0449394
Rush	I:C0449394
staging	I:C0449394
model	I:C0449394
(	O
Thase	O
and	I:C0449394
Rush	I:C0449394
staging	I:C0449394
model	I:C0449394
)	O
and	O
the	O
Maudsley	O
Staging	I:C0449394
Model	I:C0449394
(	O
Maudsley	O
Staging	I:C0449394
Model	I:C0449394
)	O
.	O

This	O
study	O
aimed	O
to	O
use	O
recently	O
advanced	O
high	O
-	I:C0872252
throughput	I:C0872252
proteomic	I:C0872252
platforms	I:C0872252
to	O
identify	O
peripheral	O
biomarkers	O
of	O
treatment	O
-	I:C2063866
resistant	I:C2063866
depression	I:C2063866
defined	O
by	O
two	O
staging	O
models	I:C0449394
,	O
the	O
Thase	O
and	I:C0449394
Rush	I:C0449394
staging	I:C0449394
model	I:C0449394
(	O
Thase	B:C0449394
and	I:C0449394
Rush	I:C0449394
staging	I:C0449394
model	I:C0449394
)	O
and	O
the	O
Maudsley	O
Staging	I:C0449394
Model	I:C0449394
(	O
Maudsley	O
Staging	I:C0449394
Model	I:C0449394
)	O
.	O

This	O
study	O
aimed	O
to	O
use	O
recently	O
advanced	O
high	O
-	I:C0872252
throughput	I:C0872252
proteomic	I:C0872252
platforms	I:C0872252
to	O
identify	O
peripheral	O
biomarkers	O
of	O
treatment	O
-	I:C2063866
resistant	I:C2063866
depression	I:C2063866
defined	O
by	O
two	O
staging	O
models	I:C0449394
,	O
the	O
Thase	O
and	I:C0449394
Rush	I:C0449394
staging	I:C0449394
model	I:C0449394
(	O
Thase	O
and	I:C0449394
Rush	I:C0449394
staging	I:C0449394
model	I:C0449394
)	O
and	O
the	O
Maudsley	B:C0449394
Staging	I:C0449394
Model	I:C0449394
(	O
Maudsley	O
Staging	I:C0449394
Model	I:C0449394
)	O
.	O

This	O
study	O
aimed	O
to	O
use	O
recently	O
advanced	O
high	O
-	I:C0872252
throughput	I:C0872252
proteomic	I:C0872252
platforms	I:C0872252
to	O
identify	O
peripheral	O
biomarkers	O
of	O
treatment	O
-	I:C2063866
resistant	I:C2063866
depression	I:C2063866
defined	O
by	O
two	O
staging	O
models	I:C0449394
,	O
the	O
Thase	O
and	I:C0449394
Rush	I:C0449394
staging	I:C0449394
model	I:C0449394
(	O
Thase	O
and	I:C0449394
Rush	I:C0449394
staging	I:C0449394
model	I:C0449394
)	O
and	O
the	O
Maudsley	O
Staging	I:C0449394
Model	I:C0449394
(	O
Maudsley	B:C0449394
Staging	I:C0449394
Model	I:C0449394
)	O
.	O

Serum	B:C0229671
collected	O
from	O
an	O
inpatient	O
cohort	O
of	O
65	O
individuals	O
suffering	O
from	O
major	O
depressive	I:C1269683
disorder	I:C1269683
was	O
analysed	O
using	O
two	O
different	O
mass	O
spectrometric	I:C0037813
-	I:C0037813
based	I:C0037813
platforms	I:C0037813
,	O
label	O
-	I:C0872318
free	I:C0872318
liquid	I:C0872318
chromatography	I:C0872318
mass	I:C0872318
spectrometry	I:C0872318
(	O
liquid	O
chromatography	I:C0872318
mass	I:C0872318
spectrometry	I:C0872318
)	O
and	O
selective	O
reaction	O
monitoring	O
(	O
SRM	O
)	O
,	O
as	O
well	O
as	O
a	O
multiplex	O
bead	I:C0020980
based	I:C0020980
assay	I:C0020980
.	O

Serum	O
collected	O
from	O
an	O
inpatient	O
cohort	O
of	O
65	O
individuals	B:C0027361
suffering	O
from	O
major	O
depressive	I:C1269683
disorder	I:C1269683
was	O
analysed	O
using	O
two	O
different	O
mass	O
spectrometric	I:C0037813
-	I:C0037813
based	I:C0037813
platforms	I:C0037813
,	O
label	O
-	I:C0872318
free	I:C0872318
liquid	I:C0872318
chromatography	I:C0872318
mass	I:C0872318
spectrometry	I:C0872318
(	O
liquid	O
chromatography	I:C0872318
mass	I:C0872318
spectrometry	I:C0872318
)	O
and	O
selective	O
reaction	O
monitoring	O
(	O
SRM	O
)	O
,	O
as	O
well	O
as	O
a	O
multiplex	O
bead	I:C0020980
based	I:C0020980
assay	I:C0020980
.	O

Serum	O
collected	O
from	O
an	O
inpatient	O
cohort	O
of	O
65	O
individuals	O
suffering	O
from	O
major	B:C1269683
depressive	I:C1269683
disorder	I:C1269683
was	O
analysed	O
using	O
two	O
different	O
mass	O
spectrometric	I:C0037813
-	I:C0037813
based	I:C0037813
platforms	I:C0037813
,	O
label	O
-	I:C0872318
free	I:C0872318
liquid	I:C0872318
chromatography	I:C0872318
mass	I:C0872318
spectrometry	I:C0872318
(	O
liquid	O
chromatography	I:C0872318
mass	I:C0872318
spectrometry	I:C0872318
)	O
and	O
selective	O
reaction	O
monitoring	O
(	O
SRM	O
)	O
,	O
as	O
well	O
as	O
a	O
multiplex	O
bead	I:C0020980
based	I:C0020980
assay	I:C0020980
.	O

Serum	O
collected	O
from	O
an	O
inpatient	O
cohort	O
of	O
65	O
individuals	O
suffering	O
from	O
major	O
depressive	I:C1269683
disorder	I:C1269683
was	O
analysed	O
using	O
two	O
different	O
mass	B:C0037813
spectrometric	I:C0037813
-	I:C0037813
based	I:C0037813
platforms	I:C0037813
,	O
label	O
-	I:C0872318
free	I:C0872318
liquid	I:C0872318
chromatography	I:C0872318
mass	I:C0872318
spectrometry	I:C0872318
(	O
liquid	O
chromatography	I:C0872318
mass	I:C0872318
spectrometry	I:C0872318
)	O
and	O
selective	O
reaction	O
monitoring	O
(	O
SRM	O
)	O
,	O
as	O
well	O
as	O
a	O
multiplex	O
bead	I:C0020980
based	I:C0020980
assay	I:C0020980
.	O

Serum	O
collected	O
from	O
an	O
inpatient	O
cohort	O
of	O
65	O
individuals	O
suffering	O
from	O
major	O
depressive	I:C1269683
disorder	I:C1269683
was	O
analysed	O
using	O
two	O
different	O
mass	O
spectrometric	I:C0037813
-	I:C0037813
based	I:C0037813
platforms	I:C0037813
,	O
label	B:C0872318
-	I:C0872318
free	I:C0872318
liquid	I:C0872318
chromatography	I:C0872318
mass	I:C0872318
spectrometry	I:C0872318
(	O
liquid	O
chromatography	I:C0872318
mass	I:C0872318
spectrometry	I:C0872318
)	O
and	O
selective	O
reaction	O
monitoring	O
(	O
SRM	O
)	O
,	O
as	O
well	O
as	O
a	O
multiplex	O
bead	I:C0020980
based	I:C0020980
assay	I:C0020980
.	O

Serum	O
collected	O
from	O
an	O
inpatient	O
cohort	O
of	O
65	O
individuals	O
suffering	O
from	O
major	O
depressive	I:C1269683
disorder	I:C1269683
was	O
analysed	O
using	O
two	O
different	O
mass	O
spectrometric	I:C0037813
-	I:C0037813
based	I:C0037813
platforms	I:C0037813
,	O
label	O
-	I:C0872318
free	I:C0872318
liquid	I:C0872318
chromatography	I:C0872318
mass	I:C0872318
spectrometry	I:C0872318
(	O
liquid	B:C0872318
chromatography	I:C0872318
mass	I:C0872318
spectrometry	I:C0872318
)	O
and	O
selective	O
reaction	O
monitoring	O
(	O
SRM	O
)	O
,	O
as	O
well	O
as	O
a	O
multiplex	O
bead	I:C0020980
based	I:C0020980
assay	I:C0020980
.	O

Serum	O
collected	O
from	O
an	O
inpatient	O
cohort	O
of	O
65	O
individuals	O
suffering	O
from	O
major	O
depressive	I:C1269683
disorder	I:C1269683
was	O
analysed	O
using	O
two	O
different	O
mass	O
spectrometric	I:C0037813
-	I:C0037813
based	I:C0037813
platforms	I:C0037813
,	O
label	O
-	I:C0872318
free	I:C0872318
liquid	I:C0872318
chromatography	I:C0872318
mass	I:C0872318
spectrometry	I:C0872318
(	O
liquid	O
chromatography	I:C0872318
mass	I:C0872318
spectrometry	I:C0872318
)	O
and	O
selective	O
reaction	O
monitoring	O
(	O
SRM	O
)	O
,	O
as	O
well	O
as	O
a	O
multiplex	B:C0020980
bead	I:C0020980
based	I:C0020980
assay	I:C0020980
.	O

In	O
the	O
LC	B:C0872318
-	I:C0872318
MS	I:C0872318
(	I:C0872318
E	I:C0872318
)	I:C0872318
analysis	I:C0872318
,	O
proteins	O
involved	O
in	O
the	O
acute	O
phase	I:C0001349
response	I:C0001349
and	O
complement	O
activation	I:C0009528
and	O
coagulation	O
were	O
significantly	O
different	O
between	O
the	O
staging	O
groups	I:C0449394
in	O
both	O
models	O
.	O

In	O
the	O
LC	O
-	I:C0872318
MS	I:C0872318
(	I:C0872318
E	I:C0872318
)	I:C0872318
analysis	I:C0872318
,	O
proteins	B:C0033684
involved	O
in	O
the	O
acute	O
phase	I:C0001349
response	I:C0001349
and	O
complement	O
activation	I:C0009528
and	O
coagulation	O
were	O
significantly	O
different	O
between	O
the	O
staging	O
groups	I:C0449394
in	O
both	O
models	O
.	O

In	O
the	O
LC	O
-	I:C0872318
MS	I:C0872318
(	I:C0872318
E	I:C0872318
)	I:C0872318
analysis	I:C0872318
,	O
proteins	O
involved	O
in	O
the	O
acute	B:C0001349
phase	I:C0001349
response	I:C0001349
and	O
complement	O
activation	I:C0009528
and	O
coagulation	O
were	O
significantly	O
different	O
between	O
the	O
staging	O
groups	I:C0449394
in	O
both	O
models	O
.	O

In	O
the	O
LC	O
-	I:C0872318
MS	I:C0872318
(	I:C0872318
E	I:C0872318
)	I:C0872318
analysis	I:C0872318
,	O
proteins	O
involved	O
in	O
the	O
acute	O
phase	I:C0001349
response	I:C0001349
and	O
complement	B:C0009528
activation	I:C0009528
and	O
coagulation	O
were	O
significantly	O
different	O
between	O
the	O
staging	O
groups	I:C0449394
in	O
both	O
models	O
.	O

In	O
the	O
LC	O
-	I:C0872318
MS	I:C0872318
(	I:C0872318
E	I:C0872318
)	I:C0872318
analysis	I:C0872318
,	O
proteins	O
involved	O
in	O
the	O
acute	O
phase	I:C0001349
response	I:C0001349
and	O
complement	O
activation	I:C0009528
and	O
coagulation	B:C1328723
were	O
significantly	O
different	O
between	O
the	O
staging	O
groups	I:C0449394
in	O
both	O
models	O
.	O

In	O
the	O
LC	O
-	I:C0872318
MS	I:C0872318
(	I:C0872318
E	I:C0872318
)	I:C0872318
analysis	I:C0872318
,	O
proteins	O
involved	O
in	O
the	O
acute	O
phase	I:C0001349
response	I:C0001349
and	O
complement	O
activation	I:C0009528
and	O
coagulation	O
were	O
significantly	O
different	O
between	O
the	O
staging	B:C0449394
groups	I:C0449394
in	O
both	O
models	O
.	O

In	O
the	O
LC	O
-	I:C0872318
MS	I:C0872318
(	I:C0872318
E	I:C0872318
)	I:C0872318
analysis	I:C0872318
,	O
proteins	O
involved	O
in	O
the	O
acute	O
phase	I:C0001349
response	I:C0001349
and	O
complement	O
activation	I:C0009528
and	O
coagulation	O
were	O
significantly	O
different	O
between	O
the	O
staging	O
groups	I:C0449394
in	O
both	O
models	B:C0449394
.	O

In	O
the	O
multiplex	B:C0020980
bead	I:C0020980
-	I:C0020980
based	I:C0020980
assay	I:C0020980
analysis	O
TNF	O
-α	I:C1168005
levels	I:C1168005
(	O
log(	O
odds	O
)	O
=	O
-	O
4.95	O
,	O
p	O
=	O
0.045	O
)	O
were	O
significantly	O
different	O
in	O
the	O
Thase	O
and	I:C0449394
Rush	I:C0449394
staging	I:C0449394
model	I:C0449394
comparison	O
.	O

In	O
the	O
multiplex	O
bead	I:C0020980
-	I:C0020980
based	I:C0020980
assay	I:C0020980
analysis	O
TNF	B:C1168005
-α	I:C1168005
levels	I:C1168005
(	O
log(	O
odds	O
)	O
=	O
-	O
4.95	O
,	O
p	O
=	O
0.045	O
)	O
were	O
significantly	O
different	O
in	O
the	O
Thase	O
and	I:C0449394
Rush	I:C0449394
staging	I:C0449394
model	I:C0449394
comparison	O
.	O

In	O
the	O
multiplex	O
bead	I:C0020980
-	I:C0020980
based	I:C0020980
assay	I:C0020980
analysis	O
TNF	O
-α	I:C1168005
levels	I:C1168005
(	O
log(	O
odds	O
)	O
=	O
-	O
4.95	O
,	O
p	O
=	O
0.045	O
)	O
were	O
significantly	O
different	O
in	O
the	O
Thase	B:C0449394
and	I:C0449394
Rush	I:C0449394
staging	I:C0449394
model	I:C0449394
comparison	O
.	O

Using	O
SRM	O
,	O
significant	O
changes	O
of	O
three	O
apolipoproteins	B:C0085201
A	I:C0085201
-	I:C0085201
I	I:C0085201
(	O
β	O
=	O
0.029	O
,	O
p	O
=	O
0.035	O
)	O
,	O
M	O
(β	O
=	O
-	O
0.017	O
,	O
p	O
=	O
0.009	O
)	O
and	O
F	O
(β	O
=	O
-	O
0.031	O
,	O
p	O
=	O
0.024	O
)	O
were	O
associated	O
with	O
the	O
Thase	O
and	I:C0449394
Rush	I:C0449394
staging	I:C0449394
model	I:C0449394
but	O
not	O
the	O
Maudsley	O
Staging	I:C0449394
Model	I:C0449394
.	O

Using	O
SRM	O
,	O
significant	O
changes	O
of	O
three	O
apolipoproteins	O
A	I:C0085201
-	I:C0085201
I	I:C0085201
(	O
β	O
=	O
0.029	O
,	O
p	O
=	O
0.035	O
)	O
,	O
M	B:C1438565
(β	O
=	O
-	O
0.017	O
,	O
p	O
=	O
0.009	O
)	O
and	O
F	O
(β	O
=	O
-	O
0.031	O
,	O
p	O
=	O
0.024	O
)	O
were	O
associated	O
with	O
the	O
Thase	O
and	I:C0449394
Rush	I:C0449394
staging	I:C0449394
model	I:C0449394
but	O
not	O
the	O
Maudsley	O
Staging	I:C0449394
Model	I:C0449394
.	O

Using	O
SRM	O
,	O
significant	O
changes	O
of	O
three	O
apolipoproteins	O
A	I:C0085201
-	I:C0085201
I	I:C0085201
(	O
β	O
=	O
0.029	O
,	O
p	O
=	O
0.035	O
)	O
,	O
M	O
(β	O
=	O
-	O
0.017	O
,	O
p	O
=	O
0.009	O
)	O
and	O
F	B:C0052208
(β	O
=	O
-	O
0.031	O
,	O
p	O
=	O
0.024	O
)	O
were	O
associated	O
with	O
the	O
Thase	O
and	I:C0449394
Rush	I:C0449394
staging	I:C0449394
model	I:C0449394
but	O
not	O
the	O
Maudsley	O
Staging	I:C0449394
Model	I:C0449394
.	O

Using	O
SRM	O
,	O
significant	O
changes	O
of	O
three	O
apolipoproteins	O
A	I:C0085201
-	I:C0085201
I	I:C0085201
(	O
β	O
=	O
0.029	O
,	O
p	O
=	O
0.035	O
)	O
,	O
M	O
(β	O
=	O
-	O
0.017	O
,	O
p	O
=	O
0.009	O
)	O
and	O
F	O
(β	O
=	O
-	O
0.031	O
,	O
p	O
=	O
0.024	O
)	O
were	O
associated	O
with	O
the	O
Thase	B:C0449394
and	I:C0449394
Rush	I:C0449394
staging	I:C0449394
model	I:C0449394
but	O
not	O
the	O
Maudsley	O
Staging	I:C0449394
Model	I:C0449394
.	O

Using	O
SRM	O
,	O
significant	O
changes	O
of	O
three	O
apolipoproteins	O
A	I:C0085201
-	I:C0085201
I	I:C0085201
(	O
β	O
=	O
0.029	O
,	O
p	O
=	O
0.035	O
)	O
,	O
M	O
(β	O
=	O
-	O
0.017	O
,	O
p	O
=	O
0.009	O
)	O
and	O
F	O
(β	O
=	O
-	O
0.031	O
,	O
p	O
=	O
0.024	O
)	O
were	O
associated	O
with	O
the	O
Thase	O
and	I:C0449394
Rush	I:C0449394
staging	I:C0449394
model	I:C0449394
but	O
not	O
the	O
Maudsley	B:C0449394
Staging	I:C0449394
Model	I:C0449394
.	O

Overall	O
,	O
our	O
findings	B:C0243095
suggest	O
that	O
proteins	O
,	O
which	O
are	O
involved	O
in	O
immune	O
and	O
complement	O
activation	I:C0009528
,	O
may	O
represent	O
potential	O
biomarkers	O
that	O
could	O
be	O
used	O
by	O
clinicians	O
to	O
identify	O
high	O
-	I:C0332167
risk	I:C0332167
patients	O
.	O

Overall	O
,	O
our	O
findings	O
suggest	O
that	O
proteins	B:C0033684
,	O
which	O
are	O
involved	O
in	O
immune	O
and	O
complement	O
activation	I:C0009528
,	O
may	O
represent	O
potential	O
biomarkers	O
that	O
could	O
be	O
used	O
by	O
clinicians	O
to	O
identify	O
high	O
-	I:C0332167
risk	I:C0332167
patients	O
.	O

Overall	O
,	O
our	O
findings	O
suggest	O
that	O
proteins	O
,	O
which	O
are	O
involved	O
in	O
immune	B:C1155000
and	O
complement	O
activation	I:C0009528
,	O
may	O
represent	O
potential	O
biomarkers	O
that	O
could	O
be	O
used	O
by	O
clinicians	O
to	O
identify	O
high	O
-	I:C0332167
risk	I:C0332167
patients	O
.	O

Overall	O
,	O
our	O
findings	O
suggest	O
that	O
proteins	O
,	O
which	O
are	O
involved	O
in	O
immune	O
and	O
complement	B:C0009528
activation	I:C0009528
,	O
may	O
represent	O
potential	O
biomarkers	O
that	O
could	O
be	O
used	O
by	O
clinicians	O
to	O
identify	O
high	O
-	I:C0332167
risk	I:C0332167
patients	O
.	O

Overall	O
,	O
our	O
findings	O
suggest	O
that	O
proteins	O
,	O
which	O
are	O
involved	O
in	O
immune	O
and	O
complement	O
activation	I:C0009528
,	O
may	O
represent	O
potential	O
biomarkers	B:C0005516
that	O
could	O
be	O
used	O
by	O
clinicians	O
to	O
identify	O
high	O
-	I:C0332167
risk	I:C0332167
patients	O
.	O

Overall	O
,	O
our	O
findings	O
suggest	O
that	O
proteins	O
,	O
which	O
are	O
involved	O
in	O
immune	O
and	O
complement	O
activation	I:C0009528
,	O
may	O
represent	O
potential	O
biomarkers	O
that	O
could	O
be	O
used	O
by	O
clinicians	B:C0871685
to	O
identify	O
high	O
-	I:C0332167
risk	I:C0332167
patients	O
.	O

Overall	O
,	O
our	O
findings	O
suggest	O
that	O
proteins	O
,	O
which	O
are	O
involved	O
in	O
immune	O
and	O
complement	O
activation	I:C0009528
,	O
may	O
represent	O
potential	O
biomarkers	O
that	O
could	O
be	O
used	O
by	O
clinicians	O
to	O
identify	O
high	B:C0332167
-	I:C0332167
risk	I:C0332167
patients	O
.	O

Nevertheless	O
,	O
given	O
that	O
the	O
molecular	O
changes	O
between	O
the	O
staging	B:C0449394
groups	I:C0449394
were	O
subtle	O
,	O
the	O
results	O
need	O
to	O
be	O
interpreted	O
cautiously	O
.	O

